Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

IntroductionType 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin-producing β cells of the pancreas. One immunosuppressive agent that has recently shown promise in the treatment of new-onset T1D subjects aged 12–45 years is antithymocyte globu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ open 2021-12, Vol.11 (12), p.e053669-e053669
Hauptverfasser:	Wilhelm-Benartzi, Charlotte S, Miller, Sarah E, Bruggraber, Sylvaine, Picton, Diane, Wilson, Mark, Gatley, Katrina, Chhabra, Anita, Marcovecchio, M Loredana, Hendriks, A Emile J, Morobé, Hilde, Chmura, Piotr Jaroslaw, Bond, Simon, Aschemeier-Fuchs, Bärbel, Knip, Mikael, Tree, Timothy, Overbergh, Lut, Pall, Jaivier, Arnaud, Olivier, Haller, Michael J, Nitsche, Almut, Schulte, Anke M, Mathieu, Chantal, Mander, Adrian, Dunger, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Adults Age Antilymphocyte Serum - therapeutic use Apoptosis Blood Glucose Blood Glucose Self-Monitoring Child Clinical trials Clinical Trials, Phase II as Topic Diabetes Diabetes and Endocrinology Diabetes Mellitus, Type 1 - drug therapy Drug dosages general diabetes Humans Hypoglycemia Immune system Immunosuppressive agents Insulin Lymphocytes Medical diagnosis Middle Aged Multicenter Studies as Topic paediatric endocrinology Pediatrics Peptides Pharmacokinetics Randomized Controlled Trials as Topic Signal transduction statistics & research methods Thymocytes Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!